Is Cytek Biosciences Inc (CTKB) overvalued? · rev $200.5M
Cytek Biosciences Inc (CTKB) is a medical devices company listed on US.
This page asks whether Cytek Biosciences Inc (CTKB) looks expensive on cached numbers — not a short thesis.
Latest reported CTKB revenue for 2024-12-31 was $200.5M. Net income was -$6.0M. Revenue was up 3.9% from 2023-12-31 to 2024-12-31. CTKB currently screens at market cap $421.8M.
CTKB currently screens at market cap $421.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CTKB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CTKB stock page for the full model, not this heading.
Not investment advice.